FROM Robert Klitzman
Home Genetic Testing New technology is flooding the market with home genetics testing. For $99 and a swab of your cheek, 23andMe offers consumers ancestry data and, until recently, personalized information about genetic traits and health conditions. In November, that part of the service was suspended, when the Food and Drug Administration ordered the company to stop marketing what it claims is a diagnostic device requiring FDA pre-approval. Kira Peikoff is a graduate student in bioethics at Columbia University. She was curious to see what we're missing with the FDA ban in place, and decided to compare the accuracy of three of the home genetics testing kits.
Replacing Obamacare: Now you see it… now you don’t As the Senate deliberates replacing Obmacare, health coverage for millions of people is at stake. There've been no public hearings, and a draft measure won't be made public. Is the House version so unpopular that that Senate is hiding a version that looks much the same?
Who's to blame for the opioid crisis? Some of the lawyers who took on Big Tobacco are now going after Big Pharma. It’s all about the deadly epidemic of opioid use. Are the drug companies to blame? What about the users? Later, on today’s Talking Point: making sense of Britain’s upset election.
Is the threat from Russia missing from the Russia meddling probe? There's much being made about the Trump administration's possible ties with Russia. But the bottom line is Russia's effort to influence American democracy. Do the President and his aides care enough to take action before voters go back to the polls?
Will the Senate write a healthcare bill in secret? While Democrats and Republicans argue White House relations with Russia, another question is being decided behind closed doors: who gets help buying health insurance and who doesn't? We hear how the pros and cons are being shrouded in secrecy.